Long-acting β2 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 4, 2012, Pages 312-318

  Perng, Diahn Warng ^a,b   Su, Kang Cheng ^a   Chou, Kun Ta ^a   Wu, Yu Chung ^a,b   Chen, Chun Sheng ^a   Hsiao, Yi Han ^a   Tseng, Ching Min ^a   Chen, Yu Hsuan ^a   Hsueh, Tun Yun ^a   Lee, Yu Chin ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anti inflammation; Corticosteroid; Histone deacetylase; Long acting 2 agonist; Macrophage

Indexed keywords

BUDESONIDE; FLUTICASONE; FORMOTEROL; GELATINASE B; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HYDROGEN PEROXIDE; INTERLEUKIN 8; SALMETEROL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CELL LYSATE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HISTONE DEACETYLASES; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-8; MACROPHAGES, ALVEOLAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OXIDANTS; RNA, MESSENGER;

EID: 84864064044     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.04.001     Document Type: Article

References (32)

1. National Institutes of Health. National Heart L, and Blood Institute. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report; 2001.
2. Balzano G., Stefanelli F., Iorio C., De Felice A., Melillo E.M., Martucci M., et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999, 160:1486-1492.
3. Hattotuwa K.L., Gizycki M.J., Ansari T.W., Jeffery P.K., Barnes N.C. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002, 165:1592-1596.
4. Lacoste J.Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993, 92:537-548.
5. Peleman R.A., Rytila P.H., Kips J.C., Joos G.F., Pauwels R.A. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:839-843.
6. Churg A., Wang R., Wang X., Onnervik P.O., Thim K., Wright J.L. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007, 62:706-713.
7. Finkelstein R., Fraser R.S., Ghezzo H., Cosio M.G. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995, 152:1666-1672.
8. Perng D.W., Huang H.Y., Chen H.M., Lee Y.C., Perng R.P. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004, 126:375-381.
9. Stanescu D., Sanna A., Veriter C., Kostianev S., Calcagni P.G., Fabbri L.M., et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996, 51:267-271.
10. Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., Maestrelli P., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277-1285.
11. Beato M. Chromatin structure and the regulation of gene expression: remodeling at the MMTV promoter. J Mol Med 1996, 74:711-724.
12. Wu R.S., Panusz H.T., Hatch C.L., Bonner W.M. Histones and their modifications. CRC Crit Rev Biochem 1986, 20:201-263.
13. Pazin M.J., Kadonaga J.T. What's up and down with histone deacetylation and transcription?. Cell 1997, 89:325-328.
14. Ito K., Lim S., Caramori G., Chung K.F., Barnes P.J., Adcock I.M. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001, 15:1110-1112.
15. Ito K., Ito M., Elliott W.M., Cosio B., Caramori G., Kon O.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352:1967-1976.
16. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
17. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81.
18. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., Stockley R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
19. Culpitt S.V., Maziak W., Loukidis S., Nightingale J.A., Matthews J.L., Barnes P.J. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:1635-1639.
20. Gizycki M.J., Hattotuwa K.L., Barnes N., Jeffery P.K. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002, 57:799-803.
21. Bourbeau J., Christodoulopoulos P., Maltais F., Yamauchi Y., Olivenstein R., Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007, 62:938-943.
22. Barnes N.C., Qiu Y.S., Pavord I.D., Parker D., Davis P.A., Zhu J., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 173:736-743.
23. Perng D.W., Tao C.W., Su K.C., Tsai C.C., Liu L.Y., Lee Y.C. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009, 33:778-784.
24. Scheel-Toellner D., Wang K., Craddock R., Webb P.R., McGettrick H.M., Assi L.K., et al. Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood 2004, 104:2557-2564.
25. Sarir H., Mortaz E., Karimi K., Johnson M., Nijkamp F.P., Folkerts G. Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages. Eur J Pharmacol 2007, 571:55-61.
26. Spoelstra F.M., Postma D.S., Hovenga H., Noordhoek J.A., Kauffman H.F. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 2002, 57:237-241.
27. Hauck R.W., Harth M., Schulz C., Prauer H., Bohm M., Schomig A. Effects of beta 2-agonist- and dexamethasone-treatment on relaxation and regulation of beta-adrenoceptors in human bronchi and lung tissue. Br J Pharmacol 1997, 121:1523-1530.
28. Cosio B.G., Tsaprouni L., Ito K., Jazrawi E., Adcock I.M., Barnes P.J. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200:689-695.
29. Ito K., Lim S., Caramori G., Cosio B., Chung K.F., Adcock I.M., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002, 99:8921-8926.
30. Rennard S.I., Basset G., Lecossier D., O'Donnell K.M., Pinkston P., Martin P.G., et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986, 60:532-538.
31. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma - a randomized controlled trial. Am J Resp Crit Care Med 2001, 163:32-36.
32. Woodruff P.G., Ellwanger A., Solon M., Cambier C.J., Pinkerton K.E., Koth L.L. Alveolar macrophage recruitment and activation by chronic second hand smoke exposure in mice. Copd 2009, 6:86-94.